TY - JOUR
T1 - Overall Survival in Metastatic Breast Cancer Patients in the Third Millennium: Results of the COSMO Study
AU - La Verde, Nicla
AU - Collovà, Elena
AU - Blasi, Livio
AU - Pinotti, Graziella
AU - Palumbo, Raffaella
AU - Bonotto, Marta
AU - Garrone, Ornella
AU - Brunello, Antonella
AU - Rimanti, Anita
AU - Bareggi, Claudia
AU - Zaniboni, Alberto
AU - Frassoldati, Antonio
AU - Foglietta, Jennifer
AU - Berardi, Rossana
AU - Moretti, Anna
AU - Farina, Gabriella
AU - Porcu, Luca
AU - Barni, Sandro
N1 - Funding Information:
The COSMO group comprises: Vita Leonardi (Department of Oncology, Azienda Civico e Benfratelli, di Cristina ARNAS Palermo, Italy), Stefania Gori (IRCCS Ospedale Sacro Cuore?Don Calabria, Negrar, Italy), Ilaria Vallini, Linda Bascialla (Department of Oncology, ASST-Settelaghi Varese, Italy), Sara Mariucci (Operative Unit of Medical Oncology, IRCCS-ICS Maugeri, Pavia, Italy), Lorenzo Gerratana (Department of Oncology, University Hospital of Udine, Italy), Emanuela Miraglio, Paola Vennella (Department of Oncology, S. Croce & Carle Teaching Hospital, Cuneo, Italy), Selma Ahcene-Djaballah, Grazia Pusole (Medical Oncology Unit 1, Istituto Oncologico Veneto-IRCCS, Padova, Italy), Beatrice Vivorio, Patrizia Morselli (Department of Oncology, ASST Mantova, AO Carlo Poma, Mantova, Italy), Tiziana Prochilo, Ester Oneda (Department of Medical Oncology, Poliambulanza Foundation, Brescia, Italy), Alessio Schirone (Clinical Oncology Unit, S. Anna University Hospital, Ferrara, Italy), Mirco Pistelli (Oncology Clinic, Universit? Politecnica delle Marche, Ospedali Riuniti di Ancona, Italy), Chiara Saggia, Silvia Genestroni (Department of Oncology Azienda Ospedaliera Universitaria ?Maggiore della Carit?,? Novara, Italy), Silvana Saracchini, Manuela Bertola (Department of Oncology, IRCCS Cro-Aviano, Italy), Daniele Santini, Maria Concetta Cursano (Department of Oncology, University Campus Biomedico, Roma, Italy), Manlio Mencoboni, Carlotta Simoni (Department of Oncology Villa Scassi, Genova, Italy), Francesca Filiali, Paola Tagliabue (Department of Medical Oncology Carate Brianza, ASST di Vimercate (MI), Italy), Sara Donati (Medical Oncology, Ospedale Versilia, Tuscan Tumor Institute (ITT), Lido di Camaiore, Italy), Daniele Generali (Breast Cancer Unit and Molecular Therapy Unit, Azienda Socio Sanitaria Territoriale di Cremona, Cremona, Italy), Marianna Tudini (Department of Medical Oncology, AV2 Fabriano, ASUR Marche, Italy), Luisa Carbognin (Division of Gynecologic Oncology Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy), Elisabetta Menatti (Department of Medical Oncology ASST della Valtellina e dell'Alto Lario Presidio Ospedaliero di Sondrio, Italy), Graziano Meneghini (Breast Unit, AULSS8 Berica, Montecchio Maggiore, Vicenza, Italy), Silvia Cugudda (Department of Medical Oncology Universit? di Cagliari, Italy), Andrea Fontana (Department of Medical Oncology, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy), Alessandro Iaculli (Department of Oncology, ASST Bergamo Est, Italy), Beatrice Boido De Troia (Department of Oncology, ASST Fatebenefratelli Sacco, PO Fatebenefratelli, Milan, Italy), Davide Dalu (Department of Oncology, ASST Fatebenefratelli Sacco. PO Sacco Hospital, Milan, Italy), EISAI for supporting the open access of this publication, and Joanna Landi for technical support during the submission process.
Publisher Copyright:
© 2020 The Authors
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020/11/9
Y1 - 2020/11/9
N2 - Metastatic breast cancer remains a deadly disease despite scientific progress. The COSMO study included 3721 patients and aimed to detect a temporal variation in overall survival during the period 2000-2008 that had not yet been demonstrated. Disease-free interval, metastatic site, age at diagnosis, and tumor biology remain important factors that affect prognosis.
AB - Metastatic breast cancer remains a deadly disease despite scientific progress. The COSMO study included 3721 patients and aimed to detect a temporal variation in overall survival during the period 2000-2008 that had not yet been demonstrated. Disease-free interval, metastatic site, age at diagnosis, and tumor biology remain important factors that affect prognosis.
KW - Biological subtype
KW - Bone disease
KW - Breast cancer prognosis
KW - Disease free interval
KW - Visceral disease
UR - http://www.scopus.com/inward/record.url?scp=85097900734&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85097900734&partnerID=8YFLogxK
U2 - 10.1016/j.clbc.2020.11.001
DO - 10.1016/j.clbc.2020.11.001
M3 - Article
AN - SCOPUS:85097900734
SP - 1
EP - 8
JO - Clinical Breast Cancer
JF - Clinical Breast Cancer
SN - 1526-8209
ER -